[Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate].
Out of 62 patients with hormone-refractory metastatic prostate cancer, 34 received rescue treatment with estramustine phosphate and 28 received non-steroidal symptomatic treatment. All patients undergoing symptomatic treatment experienced increased PSA levels while in 16 (47%) patients treated with estramustine phosphate, PSA decreased between 13-96%. In 11 cases (32.3%) the decline in PSA was higher than 50%. In 5 (14.7%) the decline was lower than 50% and in 18 cases (53%) PSA levels were increased. SCR rate was 82%, 60% and 6% respectively while OCR were 36.4%., 0% and 0% respectively. No clinical response was seen in patients undergoing symptomatic treatment. A decline in PSA levels higher than 50% 12 weeks after treatment appears to be a "good prognosis" factor related to the best clinical response rates and survival.
Morote
J
J
Servicio de Urología, Hospital General Universitario Vall d'Hebron, Barcelona.
Lorente
J A
JA
Vallejo
C
C
Encabo
G
G
López-Pacios
M A
MA
De Torres
J A
JA
Soler Rosello
A
A
D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D015996:Survival Rate
D004961:Estramustine; D017430:Prostate-Specific Antigen